Craft

Advagene Biopharma

Stock Price

NT$23.9

2024-10-29

Market Capitalization

NT$1.4 B

2024-10-29

Advagene Biopharma Summary

Company Summary

Overview
Advagene Biopharma is a company that researches, develops, and distributes vaccine products. Its products include nasal spray influenza (LT-Flu), allergy vaccines (LT-Allergy), COVID-19 immunotherapy drug AD17002-SC, etc.
Type
Public
Status
Active
Website
http://www.advagene.com.tw
Cybersecurity rating
Sectors

Table of Contents

Advagene Biopharma Financials

Summary Financials

Net income (FY, 2025)
(NT$68.3M)
Cash (FY, 2025)
NT$55.3M
EBIT (FY, 2025)
(NT$70.9M)
Enterprise value
$1.4B

Footer menu